Teva Pharmaceutical Industries Limited

1. 01

   Ahead of SPY and its sector fund XLV over 1 year

   1 month: +7.0% (SPY −1.6%, XLV +13.5%). 3 months: +20.5% (SPY −0.4%, XLV +15.5%). 1 year: +104.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: TEVA, SPY and XLV · as of 4 Nov 2026

2. 02

   3.4% below its 52-week high

   Closed at $41.85 on 4 Nov 2026: 3.4% below the 52-week high of $43.34 (3 Nov 2026) and 77.3% above the low of $23.61 (7 Nov 2025).

   Daily price bars, split-adjusted · as of 4 Nov 2026

3. 03

   Above its 50- and 200-day averages

   The 4 Nov 2026 close of $41.85 was 6.4% above its 50-day average ($39.33) and 20.5% above its 200-day average ($34.73). It has closed above the 200-day for 74 sessions, since 23 Jul 2026. The 50-day average crossed above the 200-day on 16 Sep 2025, 286 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

4. 04

   Volume 1.6× its 30-session average on 4 Nov 2026

   4 Nov 2026 volume of 10.0M shares was 1.6× the average of the 30 sessions before it (6.4M), as the price fell 0.1%. SPY traded 1.5× its own average that session.

   Daily volume against a 30-session baseline · as of 4 Nov 2026

5. 05

   28.1M shares sold short

   28.1M shares were sold short at the 15 Oct 2026 settlement; covering them would take 3.9 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

At the 4 Nov 2026 close